1. Cardoso, F, Kyriakides, S, Ohno, S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1194–1220.
Google Scholar | Crossref | Medline2. Korde, LA, Somerfield, MR, Carey, LA, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 2021; 39: 1485–1505.
Google Scholar | Crossref | Medline3. Perez, EA, Romond, EH, Suman, VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 2014; 32: 3744–3752.
Google Scholar | Crossref | Medline4. Cortazar, P, Zhang, L, Untch, M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164–172.
Google Scholar | Crossref | Medline5. Masuda, N, Lee, S-J, Ohtani, S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376: 2147–2159.
Google Scholar | Crossref | Medline6. von Minckwitz, G, Huang, C-S, Mano, MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617–628.
Google Scholar | Crossref | Medline7. Baselga, J, Bradbury, I, Eidtmann, H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633–640.
Google Scholar | Crossref | Medline8. de Azambuja, E, Holmes, AP, Piccart-Gebhart, M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 2014; 15: 1137–1146.
Google Scholar | Crossref | Medline9. Huober, J, Holmes, E, Baselga, J, et al. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer 2019; 118: 169–177.
Google Scholar | Crossref | Medline10. Guarneri, V, Frassoldati, A, Bottini, A, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2–positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol 2012; 30: 1989–1995.
Google Scholar | Crossref | Medline11. Gianni, L, Pienkowski, T, Im, Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25–32.
Google Scholar | Crossref | Medline12. Gianni, L, Pienkowski, T, Im, Y-H, et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17: 791–800.
Google Scholar | Crossref | Medline13. Carey, LA, Berry, DA, Cirrincione, CT, et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 2016; 34: 542–549.
Google Scholar | Crossref | Medline14. Robidoux, A, Tang, G, Rastogi, P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP Protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1183–1192.
Google Scholar | Crossref | Medline15. Schneeweiss, A, Chia, S, Hickish, T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278–2284.
Google Scholar | Crossref | Medline16. Schneeweiss, A, Chia, S, Hickish, T, et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018; 89: 27–35.
Google Scholar | Medline17. van Ramshorst, MS, van Werkhoven, E, Honkoop, AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study. Breast 2016; 29: 153–159.
Google Scholar | Crossref | Medline18. van Ramshorst, MS, van der Voort, A, van Werkhoven, ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2018; 19: 1630–1640.
Google Scholar | Crossref | Medline19. Buzdar, AU, Ibrahim, NK, Francis, D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676–3685.
Google Scholar | Crossref | Medline20. Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. 2010; 375: 8.
Google Scholar21. Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 2014; 15: 640–647.
Google Scholar | Crossref | Medline22. Buzdar, AU, Suman, VJ, Meric-Bernstam, F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1317–1325.
Google Scholar | Crossref | Medline23. Giordano, SH, Niu, J, Chavez-MacGregor, M, et al. Estimating regimen-specific costs of chemotherapy for breast cancer: observational cohort study. Cancer 2016; 122: 3447–3455.
Google Scholar | Crossref | Medline24. Kale, HP, Carroll, NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 2016; 122: 283–289.
Google Scholar | Crossref | Medline25. Ramsey, SD, Bansal, A, Fedorenko, CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016; 34: 980–986.
Google Scholar | Crossref | Medline26. Wolff, AC, Hammond, MEH, Hicks, DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997–4013.
Google Scholar | Crossref | Medline27. Curigliano, G, Lenihan, D, Fradley, M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol 2020; 31: 171–190.
Google Scholar | Crossref | Medline28. Alba, E, Albanell, J, de la Haba, J, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial. Br J Cancer 2014; 110: 1139–1147.
Google Scholar | Crossref | Medline29. Perez, EA, Romond, EH, Suman, VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2–positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366–3373.
Google Scholar | Crossref | Medline30. Del Mastro, L, De Placido, S, Bruzzi, P, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet 2015; 385: 1863–1872.
Google Scholar | Crossref | Medline31. Untch, M, Jackisch, C, Schneeweiss, A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto–GBG 69): a randomised, phase 3 trial. Lancet Oncol 2016; 17: 345–356.
Google Scholar | Crossref | Medline32. Hurvitz, SA, Martin, M, Symmans, WF, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2018; 19: 115–126.
Google Scholar | Crossref | Medline33. Guarneri, V, Dieci, MV, Bisagni, G, et al. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study. Ann Oncol 2019; 30: 921–926.
Google Scholar | Crossref | Medline34. Kuderer, NM, Dale, DC, Crawford, J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007; 25: 3158–3167.
Google Scholar | Crossref | Medline35. Piccart, M, Procter, M, Fumagalli, D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years’ follow-up. J Clin Oncol 2021; 39: 1448–1457.
Google Scholar | Crossref | Medline36. von Minckwitz, G, Procter, M, de Azambuja, E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377: 122–131.
Google Scholar | Crossref | Medline37. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, November 2019 Sub (1975-2017) - Linked To County Attributes - Time Dependent (1990-2017) Income/Rurality, 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. SEER. https://seer.cancer.gov/statfacts/html/breast.html.
Google Scholar